Tocilizumab markedly increases rate of lower gastrointestinal perforation

SAN FRANCISCO – Patients with rheumatoid arthritis were five to nine times more likely to develop lower intestinal perforation on tocilizumab, compared with conventional synthetic disease-modifying...